http://media.soundmedicine.org/segments/050414_1.mp3
New cholesterol mediations that include a PCSK9 inhibitor, which reduces the amount of LDL cholesterol, or "bad cholesterol," in the bloodstream, are in the final stages of development. Michael Davidson, M.D., discusses how PCSK9 inhibitors work to lower LDL cholesterol, the potential side effects of drugs using such inhibitors, and how soon we can expect these medications to hit the market.